Detalle Publicación


Pharmaceutical and safety profile evaluation of novel selenocompounds with noteworthy anticancer activity

Autores: Marc, M. A. (Autor de correspondencia); Domínguez-Álvarez, E. (Autor de correspondencia); Latacz, G.; Doroz-Plonka, A.; Sanmartín Grijalba, Carmen; Spengler, G.; Handzlik, J. (Autor de correspondencia)
Título de la revista: PHARMACEUTICS
ISSN: 1999-4923
Volumen: 14
Número: 2
Páginas: 367
Fecha de publicación: 2022
Prior studies have reported the potent and selective cytotoxic, pro-apoptotic, and chemopreventive activities of a cyclic selenoanhydride and of a series of selenoesters. Some of these selenium derivatives demonstrated multidrug resistance (MDR)-reversing activity in different resistant cancer cell lines. Thus, the aim of this study was to evaluate the pharmaceutical and safety profiles of these selected selenocompounds using alternative methods in silico and in vitro. One of the main tasks of this work was to determine both the physicochemical properties and metabolic stability of these selenoesters. The obtained results proved that these tested selenocompounds could become potential candidates for novel and safe anticancer drugs with good ADMET parameters. The most favorable selenocompounds turned out to be the phthalic selenoanhydride (EDA-A6), two ketone-containing selenoesters with a 4-chlorophenyl moiety (EDA-71 and EDA-73), and a symmetrical selenodiester with a pyridine ring and two selenium atoms (EDA-119).